Home › Acute Kidney Injury › NCT07197957
Cystatin and Early AKI Detection Contrast Induced Acute Kidney Injury
RecruitingObservational study
Clinical Utility of Cystatin C in the Early Detection of Contrast Induced Acute Kidney Injury
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Subjects ages 18 years and above * Inpatients with CKD (Figure 1) * Order for CT imaging study or coronary angiography with isohexol Omnipaque) contrast media. * Pre and post contrast available * All races and ethnicity of patients are eligible. We expect to analyze approximately equal number of men and women in this study. Exclusion Criteria: * Preexisting dialysis * Patients under the age of 18 years * Pregnancy * Incarcerated individuals * Patients with impaired cognition and unable to follow consent procedures * Recent exposure to CM (within 2 days before/after procedure) * Cardiac shock * Medications that affect biomarkers, including corticosteroids, lfamethoxazoletrimethoprim
About the study
To determine the clinical utility of serum cystatin C in early detection of acute kidney injury (AKI).
Sponsor: BayCare Health System · Participants: 100 · Started: Mar 11, 2025
Contact the study team
- Tracy Johns, PharmD · Phone: 727-519-1310
Official record on ClinicalTrials.gov — NCT07197957
Locations in the U.S.
| Florida | Morton Plant Hospital, Clearwater Morton Plant North Bay Hospital, New Port Richey Mease Countryside Hospital, Safety Harbor St. Anthony's Hospital, St. Petersburg |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.